Response to: "a somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: Post hoc results from the certolizumab pegol phase 4 PREDICT trial"

Madison, A., Andersen, B. L., & Ajam, A. (2019, February 20). Response to: “a somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: Post hoc results from the certolizumab pegol phase 4 PREDICT trial.” Arthritis Research and Therapy. BioMed Central Ltd. https://doi.org/10.1186/s13075-019-1848-4